The healthcare industry is evolving at an unprecedented pace, driven by rapid technological innovations, precision medicine, digital therapeutics, and an increasingly complex regulatory landscape. Pharmaceutical companies, biotech innovators, medical device manufacturers, and investors require reliable, data-driven intelligence to navigate these changes and capitalize on emerging opportunities. Market research firms that combine scientific expertise, advanced analytics, and a deep understanding of global healthcare dynamics are becoming indispensable partners in shaping strategic decisions.
As we move toward 2025, several emerging healthcare market research companies are poised to lead the next wave of innovation. These firms are gaining recognition for their ability to provide actionable insights, high-quality primary and secondary research, and strategic advisory services tailored to the evolving needs of the healthcare ecosystem.
IQVIA continues to be a dominant force in the healthcare analytics and market intelligence space. Known for its expansive data ecosystem and global reach, IQVIA provides unmatched insights into therapeutic trends, patient pathways, and market opportunities. The company leverages advanced real-world evidence (RWE), claims data, and electronic health records (EHRs) to deliver robust forecasts and predictive analytics.
In addition to traditional market intelligence, IQVIA integrates AI-powered solutions to optimize portfolio management, commercialization strategies, and clinical development planning. Their expertise spans pharmaceuticals, biotechnology, and medical devices, making IQVIA a trusted partner for global stakeholders seeking strategic insights in both established and emerging markets. By 2025, IQVIA’s continued expansion in digital health analytics and real-world evidence generation is expected to reinforce its position as a market leader.
GlobalData Healthcare has emerged as a critical provider of healthcare market intelligence, offering deep analytical insights into therapeutic segments, pipeline developments, and competitive landscapes. The company specializes in evaluating unmet medical needs, late-stage drug pipelines, and regulatory environments, providing clients with comprehensive tools for investment planning, market entry, and portfolio optimization.
GlobalData’s cardiovascular, oncology, and rare disease reports are particularly well-regarded, offering granular insights into market sizing, patient populations, and treatment adoption trends. Additionally, the firm’s proprietary intelligence platforms allow for real-time monitoring of clinical trials, drug approvals, and emerging therapeutic trends. By 2025, GlobalData is expected to expand its portfolio further, integrating AI and machine learning to deliver predictive insights and actionable market intelligence across multiple therapeutic domains.
Frost & Sullivan has long been recognized for its strategic consulting and market research capabilities. The firm combines traditional market research with innovative analytics, helping clients identify growth opportunities, emerging technologies, and strategic partnerships. Its healthcare practice is particularly focused on identifying disruptive innovations in pharmaceuticals, medical devices, digital health, and precision medicine.
The company’s cardiovascular, oncology, and diagnostic market analyses provide actionable intelligence on treatment adoption, reimbursement trends, and patient behavior, allowing clients to make informed decisions in complex markets. Frost & Sullivan’s rigorous analytical frameworks, combined with their global network of industry experts, position them as a go-to partner for stakeholders seeking to anticipate and capitalize on market evolution.
DelveInsight has established itself as a specialized healthcare market research and consulting firm with significant influence in emerging pharmaceutical and biotech markets. Known for its detailed therapeutic area intelligence, DelveInsight offers comprehensive epidemiology studies, pipeline assessments, clinical trial analyses, and market forecasts across multiple geographies.
The firm’s research capabilities span over 27 therapeutic areas and include more than 7,000 indications and 27,000 pipeline drugs. DelveInsight’s primary research services encompass physician and patient interviews, KOL engagement, and market access evaluations, providing clients with actionable insights to drive R&D decisions, commercialization strategies, and investment planning.
By 2025, DelveInsight is projected to strengthen its leadership in disease-specific intelligence, supporting clients in identifying unmet needs, evaluating competitive landscapes, and optimizing portfolio strategies. Its commitment to blending primary research with advanced data analytics ensures stakeholders receive precise, actionable insights tailored to emerging market dynamics.
MarketsandMarkets has become a leading B2B market research and consulting firm, recognized for its ability to deliver comprehensive insights across high-growth healthcare segments. The firm provides data-driven market forecasts, competitor analyses, and strategic recommendations across pharmaceuticals, diagnostics, digital health, and healthcare IT.
Their KnowledgeStore platform integrates AI-based analytics with human expertise, allowing clients to track trends, assess market potential, and evaluate emerging therapeutic opportunities. MarketsandMarkets’ strength lies in its ability to identify niche growth areas and provide strategic intelligence for both established and emerging players. By 2025, the firm is expected to expand its healthcare coverage further, integrating real-world evidence and digital health insights to support stakeholders navigating a rapidly changing market landscape.
Grand View Research delivers detailed healthcare market intelligence with a focus on data-driven forecasting and actionable insights. The company specializes in pharmaceuticals, medical devices, diagnostics, and digital health, providing extensive coverage across therapeutic areas such as oncology, cardiovascular diseases, and rare disorders.
Grand View Research emphasizes combining quantitative modeling with qualitative insights to evaluate market trends, product adoption, and competitive landscapes. Their integrated approach enables clients to anticipate market dynamics, optimize product strategies, and identify growth opportunities across multiple geographies. By 2025, the firm is expected to leverage advanced predictive analytics to enhance its forecasting capabilities and provide more granular insights into emerging healthcare markets.
Syneos Health has positioned itself as a full-service healthcare solutions provider, combining clinical research capabilities with strategic consulting. Their market research division offers insights into therapeutic trends, patient behaviors, and competitive landscapes, supporting commercialization strategies and portfolio optimization.
Syneos Health employs a hybrid model that integrates primary research—such as physician interviews and patient ethnography—with secondary data analysis. This approach allows stakeholders to connect research insights directly to actionable commercial outcomes. By 2025, Syneos Health’s focus on integrating digital solutions and real-world evidence into research workflows is expected to enhance its value to global pharmaceutical and biotech clients.
In addition to its core consulting practice, Frost & Sullivan’s emerging solutions group is dedicated to identifying transformative trends in healthcare innovation. This division leverages advanced analytics, scenario modeling, and market intelligence to forecast emerging therapeutic opportunities and evaluate technological disruptions.
Their work includes deep dives into AI-driven diagnostics, telemedicine, precision medicine, and digital therapeutics, providing clients with insights to guide R&D investments, market entry strategies, and strategic partnerships. By 2025, Frost & Sullivan Emerging Solutions is expected to play a critical role in shaping how healthcare organizations anticipate and respond to emerging market trends.
Research Partnership, now part of Inizio Advisory, specializes in global primary research across pharmaceutical, medtech, and biotech markets. The firm offers customized studies including HCP interviews, patient research, brand tracking, and lifecycle management. Their expertise in multi-country research makes them particularly valuable for stakeholders entering emerging markets or seeking detailed regional insights.
By 2025, Research Partnership is expected to expand its digital research methodologies, leveraging AI-assisted data collection and advanced analytics to deliver more efficient, high-quality insights. Their ability to combine qualitative and quantitative primary research positions them as a rising leader in healthcare market intelligence.
BioInformatics Inc., part of the Science and Medicine Group, focuses on providing research intelligence for life science tools, diagnostics, and clinical research markets. The firm combines primary research with analytics to provide actionable insights into customer behaviors, market adoption trends, and competitive positioning.
With its proprietary Science Advisory Board and global network of scientific professionals, BioInformatics Inc. delivers precise, validated insights that support product development, commercialization, and strategic planning. By 2025, the firm is expected to continue expanding its presence in the life sciences intelligence market, particularly in diagnostics and research tools.
As the healthcare landscape becomes more complex and competitive, the need for accurate, actionable, and data-driven market intelligence is greater than ever. Emerging healthcare market research companies in 2025 are not just providing information—they are strategic partners helping stakeholders navigate evolving markets, anticipate regulatory shifts, identify investment opportunities, and optimize commercialization strategies.